A once-weekly injection consisting of a fixed-dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg (Wegovy) led to ...
Novo Nordisk has an opportunity to expand indications on its weight loss drugs. Check out on what could be next for NVO stock ...
Shares of Novo Nordisk (CSE: NOVOb) continued their upward momentum on Tuesday, rising over 5%, following gains on Monday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback